Human CD4+ T lymphocytes consistently respond to the latent Epstein- Barr virus nuclear antigen EBNA1

Journal of Experimental Medicine

Volumn 191, Issue 10, 2000, Pages 1649-1660

  Münz, Christian ^a   Bickham, Kara L ^a   Subklewe, Marion ^a   Tsang, Ming L ^a   Chahroudi, Ann ^a   Kurilla, Michael G ^b,c   Zhang, Dan ^a   O'Donnell, Michael ^a   Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

CD4+ T cell; Cross presentation; Dendritic cells; Epstein Barr virus; Epstein Barr virus nuclear antigen 1

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN;

ARTICLE; B LYMPHOCYTE; CELL DIVISION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPISOME; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; EPITOPES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; PROTEIN STRUCTURE, TERTIARY; REPETITIVE SEQUENCES, AMINO ACID;

EID: 0037546559     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.10.1649     Document Type: Article

References (65)

1. Kieff, E. 1996. Epstein-Barr virus and its replication. In Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, editors. Lippincott-Raven Publishers, Philadelphia. 2343-2396.
2. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell. 77:791-793.
3. Rickinson, A.B., and E. Kieff. 1996. Epstein-Barr virus. In Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, editors. Lippincott-Raven Publishers, Philadelphia. 2397-2446.
4. Gregory, C.D., C. Dive, S. Henderson, C.A. Smith, G.T. Williams, J. Gordon, and A.B. Rickinson. 1991. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature. 349:612-614.
5. Bochkarev, A., J.A. Barwell, R.A. Pfuetzner, E. Bochkareva, L. Frappier, and A.M. Edwards. 1996. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 84:791-800.
6. Shah, W.A., R.F. Ambinder, G.S. Hayward, and S.D. Hayward. 1992. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J. Virol. 66:3355-3362.
7. Yates, J.L., N. Warren, and B. Sugden. 1985. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 313:812-815.
8. Rowe, M., A.L. Lear, D. Croom-Carter, A.H. Davies, and A.B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
9. Kaye, K.M., K.M. Izumi, G. Mosialos, and E. Kief. 1995. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J. Virol. 69:675-683.
10. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:4173-4184.
11. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:831-840.
12. Busch, L.K., and G.A. Bishop. 1999. The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. J. Immunol. 162: 2555-2561.
13. Henriquez, N.V., E. Floettmann, M. Salmon, M. Rowe, and A.B. Rickinson. 1999. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J. Immunol. 162:3298-3307.
14. Uchida, J., T. Yasui, Y. Takaoka-Shichijo, M. Muraoka, W. Kulwichit, N. Raab-Traub, and H. Kikutani. 1999. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 286:300-303.
15. Kilger, E., A. Kieser, M. Baumann, and W. Hammerschmidt. 1998. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO (Eur. Mol. Biol. Organ.) J. 17:1700-1709.
16. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. VanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 80:389-399.
17. Kieser, A., C. Kaiser, and W. Hammerschmidt. 1999. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO (Eur. Mol. Biol. Organ.) J. 18:2511-2521.
18. Gires, O., F. Kohlhuber, E. Kilger, M. Baumann, A. Kieser, C. Kaiser, R. Zeidler, B. Scheffer, M. Ueffing, and W. Hammerschmidt. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO (Eur. Mol. Biol. Organ.) J. 18:3064-3073.
19. Kieser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO (Eur. Mol. Biol. Organ.) J. 16: 6478-6485.
20. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 65:1107-1115.
21. Rowe, M., M. Peng-Pilon, D.S. Huen, R. Hardy, D. Croom-Carter, E. Lundgren, and A.B. Rickinson. 1994. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J. Virol. 68:5602-5612.
22. Caldwell, R.G., J.B. Wilson, S.J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 9:405-411.
23. Wilson, J.B., J.L. Bell, and A.J. Levine. 1996. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO (Eur. Mol. Biol. Organ.) J. 15: 3117-3126.
24. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 7:791-802.
25. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P.M. Steigerwald-Mullen, G. Klein, M.G. Kurilla, and M.G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 375:685-688.
26. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M.G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:12616-12621.
27. Sharipo, A., M. Imreh, A. Leonchiks, S. Imreh, and M.G. Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939-944.
28. Steven, N.M., A.M. Leese, N.E. Annels, S.P. Lee, and A.B. Rickinson. 1996. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 184:1801-1813.
29. Khanna, R., S.R. Burrows, J. Nicholls, and L.M. Poulsen. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur. J. Immunol. 28:451-458.
30. Lee, S.P., W.A. Thomas, N.W. Blake, and A.B. Rickinson. 1996. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur. J. Immunol. 26:1875-1883.
31. + T-helper and a T-killer cell. Nature. 393:474-478.
32. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478-480.
33. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
34. + T cells. J. Exp. Med. 184:863-871.
35. Kalams, S.A., and B.D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199-2204.
36. Zajac, A.J., J.N. Blattman, K. Murali-Krishna, D.J. Sourdive, M. Suresh, J.D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.
37. + T cell responses associated with control of viremia. Science. 278:1447-1450.
38. Rickinson, A.B., and D.J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
39. Khanna, R., S.R. Burrows, P.M. Steigerwald-Mullen, D.J. Moss, M.G. Kurilla, and L. Cooper. 1997. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int. Immunol. 9:1537-1543.
40. Steinman, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
41. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. NAture. 392:245-252.
42. Zhang, D., L. Frappier, E. Gibbs, J. Hurwitz, and M. O'Donnell. 1998. Human RPA (hSSB) interacts with EBNA1, the latent origin binding protein of Epstein-Barr virus. Nucleic Acids Res. 26:631-637.
43. Dean, F.B., and M. O'Donnell. 1996. Two steps to binding replication origins? DNA-protein interactions. Curr. Biol. 6:931-934.
44. Frappier, L., and M. O'Donnell. 1992. EBNA1 distorts oriP, the Epstein-Barr virus latent replication origin. J. Virol. 66: 1786-1790.
45. Frappier, L., and M. O'Donnell. 1991. Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus. J. Biol. Chem. 266:7819-7826.
46. Friede, T., V. Gnau, G. Jung, W. Keilholz, S. Stevanovic, and H.G. Rammensee. 1996. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim. Biophys. Acta. 1316:85-101.
47. Gorga, J.C., V. Horejsi, D.R. Johnson, R. Raghupathy, and J.L. Strominger. 1987. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J. Biol. Chem. 262:16087-16094.
48. Bender, A., M. Sapp, G. Schuler, R.M. Steinman, and N. Bhardwaj. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 196:121-135.
49. Subklewe, M., A. Chahroudi, A. Schmaljohn, M.G. Kurilla, N. Bhardwaj, and R.M. Steinman. 1999. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. Blood. 94: 1372-1381.
50. Taswell, C., H.R. MacDonald, and J.C. Cerottini. 1980. Clonal analysis of cytolytic T lymphocyte specificity. I. Phenotypically distinct sets of clones as the cellular basis of cross-reactivity to alloantigens. J. Exp. Med. 151:1372-1385.
51. +, interferon-gamma-secreting, T lymphocytes. Eur. J. Immonol. 29:3995-4001.
52. Lampson, L.A., and R. Levy. 1980. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125:293-299.
53. Engelmayer, J., M. Larsson, M. Subklewe, A. Chahroudi, W.I. Cox, R.M. Steinman, and N. Bhardwaj. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163:6762-6768.
54. + EBV-specific CTLs. J. Immunol. 158: 3619-3625.
55. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
56. Albert, M.L., S.F. Pearce, L.M. Francisco, B. Sauter, P. Roy, R.L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359-1368.
57. Cleary, M.L., M.A. Epstein, S. Finerty, R.F. Dorfman, G.W. Bornkamm, J.K. Kirkwood, A.J. Morgan, and J. Sklar. 1985. Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science. 228:722-724.
58. Wilson, A.D., M. Shooshstari, S. Finerty, P. Watkins, and A.J. Morgan. 1996. Virus-specific cycotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin. Exp. Immunol. 103:199-205.
59. Watkins, D.I., Z.W. Chen, A.L. Hughes, M.G. Evans, T.F. Tedder, and N.L. Letvin. 1990. Evolution of the MHC class I genes of a New World primate from ancestral homologues of human non-classical genes. Nature. 346:60-63.
60. + T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. Prof. Natl. Acad. Sci. USA. 96:5135-5140.
61. Schattner, E.J., K.B. Elkon, D.H. Yoo, J. Tumang, P.H. Krammer, M.K. Crow, and S.M. Friedman. 1995. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J. Exp. Med. 182:1557-1565.
62. Levine, A.M. 1992. Acquired immunodeficiency syndrome-related lymphoma. Blood. 80:8-20.
63. Sayos, J., C. Wu, M. Morra, N. Wang, X. Zhang, D. Allen, S. van Schaik, L. Notarangelo, R. Geha, M.G. Roncarolo, et al. 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:462-469.
64. Castro, A.G., T.M. Hauser, B.G., Cocks, J. Abrams, S. Zurawski, T. Churakova, F. Zonin, D. Robinson, S.G. Tangye, G. Aversa, et al. 1999. Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells. J. Immunol. 163:5860-5870.
65. Aversa, G., C.C. Chang, J.M. Carballido, B.G. Cocks, and J.E. de Vries. 1997. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J. Immunol. 158:4036-4044.